New horizons in adjuvants for vaccine development.
Over the last decade, there has been a flurry of research on adjuvants for vaccines, and several novel adjuvants are now in licensed products or in late stage clinical development. The success of adjuvants in enhancing the immune response to recombinant antigens has led many researchers to re-focus their vaccine development programs. Successful vaccine development requires knowing which adjuvants to use and knowing how to formulate adjuvants and antigens to achieve stable, safe and immunogenic vaccines. For the majority of vaccine researchers this information is not readily available, nor is access to well-characterized adjuvants. In this review, we outline the current state of adjuvant research and development and how formulation parameters can influence the effectiveness of adjuvants.
Reed
Steven G
SG
Infectious Disease Research Institute, 1124 Columbia St. Suite 400, Seattle, WA 98104, USA.
Bertholet
Sylvie
S
Coler
Rhea N
RN
Friede
Martin
M
D000276:Adjuvants, Immunologic; D000818:Animals; D015195:Drug Design; D006801:Humans; D013601:T-Lymphocytes / Q000276:immunology; D051193:Toll-Like Receptors / Q000378:metabolism; D014612:Vaccines / Q000276:immunology* / Q000378:metabolism
D000276:Adjuvants, Immunologic; D051193:Toll-Like Receptors; D014612:Vaccines